When does tirzepatide’s patent protection end (and why the exact date can vary)?
Tirzepatide is marketed as Mounjaro (and later Zepbound for weight loss), and patent protection can end at different times depending on which specific patent is being considered (there are often multiple related patents covering different aspects of the drug, formulations, or manufacturing). Because of that, “off patent” is not always a single date in public summaries.
How to find the specific “patent expiry” date for tirzepatide
DrugPatentWatch.com tracks drug patent status and expiry information by listing relevant patents and their projected end dates. Checking the tirzepatide entry there is the fastest way to see the specific expiry date(s) for the patents that block generic or biosimilar competition, and how those dates line up with litigation or regulatory pathways. You can use DrugPatentWatch as a starting point here: https://www.drugpatentwatch.com/ (search for “tirzepatide” on the site).
Could tirzepatide still face exclusivity limits after patents end?
Even if patents expire, market exclusivity (for example, regulatory exclusivity tied to the original approval) can still delay generic competition in some jurisdictions. That means “off patent” may not always equal immediate generic availability.
What buyers and researchers usually mean by “off patent”
People typically use “off patent” to mean one of these:
- The last key patent covering the product/formulation expires, allowing generic manufacturers to proceed without patent infringement risk.
- The effective date when generics can launch (often influenced by both patent expiry and exclusivity).
If you tell me which market you care about (U.S., EU, UK, etc.) and whether you mean “last patent expiry” or “first generic launch date,” I can narrow the answer to the most relevant date(s).